AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$UPB

Sutherland Everett Rand sold $12K of UPB

Sutherland Everett Rand (Chief Executive Officer) sold 2,095 shares of Upstream Bio, Inc. (UPB) at $5.49 on 2026-09-16.

Original reporting
SEC EDGAR · Sutherland Everett Rand
Published Sep 17, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 9:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UPB
Bearish
high confidence
Mentioned
$UPB
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UPBBearishLow
01

Why it matters

The CEO's modest sale slightly reduces insider ownership but is unlikely to affect valuation.

02

Market read

Minor insider sell; limited trading relevance for most investors.

03

What to watch

Potential upcoming clinical data releases could outweigh the minor sell signal.

Relevance 3/10Novelty 4/10Timing: filing date 2026-09-16

Background

Form 4 filing discloses insider transactions; required by SEC for transparency.

Company-level read

Ticker impact

$UPBBearishHigh confidence
Context

CEO Sutherland Everett Rand sold 2,095 shares for $11,501.55 on 2026-09-16, reducing his stake to 68,717 shares.

Expected impact

Minimal short-term price pressure; likely no material move.

Evidence & confidence

The transaction size (<$12K) is negligible for a public company; market typically discounts such small sales.

Market effects

Sector

No broader sector impact; insider sale is company‑specific.

Regional

None; Upstream Bio trades primarily on US exchanges.

Global

Low; micro‑cap biotech news rarely moves global markets.

Counterpoint

What could challenge this read

The sale could be unrelated personal liquidity need; investors may ignore.

Key entities

  • person
    Sutherland Everett Rand

    Chief Executive Officer of Upstream Bio, Inc.

  • company
    Upstream Bio, Inc.

    Biotech company focused on upstream oil‑field microbial solutions.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UPB insider trading history →

Related articles

$UPBMed

Upstream Bio Reports Q3 2026 Results, Plans Phase 3 Trials for 2027

Upstream Bio reported a Q3 2026 net loss of $41.2M, up from $33.7M a year earlier, with collaboration revenue of $395K. The company has $207.4M in cash, expecting to fund operations through 2027. Upstream Bio plans to start Phase 3 trials for verekitug in severe asthma and CRSwNP in Q1 2027, with additional trials in COPD and severe asthma expected to report data in 2027.

tradingview.com
$UPBMed

Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress

Upstream Bio, Inc. (UPB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress – Company plans to initiate Phase 3 trials in both severe asthma and CRSwNP in the first quarter of 2027 – – Prioritizing Phase 3 development strategy designed to deliver best-in-class eff

SEC EDGAR 8-K
$UPBMed

Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress

Upstream Bio, Inc. (UPB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress – Company rapidly advancing toward Q1 2027 initiation of Phase 3 trials designed to deliver best-in-class efficacy with convenient quarterly dosing in both severe asthma and CRSwNP; End-o

SEC EDGAR 8-K